4-(2,5-dimethyl-phenoxy)-piperidine | 946726-30-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(2,5-dimethyl-phenoxy)-piperidine
• 英文别名: 4-(2,5-Dimethylphenoxy)piperidine
• CAS: 946726-30-3
• 化学式: C₁₃H₁₉NO
• mdl: MFCD08687661
• 分子量: 205.3
• InChiKey: JKUFYLWACBCYJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(2,5-dimethyl-phenoxy)-piperidine 、 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙腈 为溶剂， 反应 4.0h， 生成 4-(2,5-dimethylphenoxy)-N-[4,4,4-trifluoro-3-hydroxy-3-(1-methylimidazol-2-yl)butyl]piperidine-1-carboxamide
  参考文献：
  名称：

  Bis(2,2,2-trifluoroethyl) Carbonate as a Condensing Agent in One-Pot Parallel Synthesis of Unsymmetrical Aliphatic Ureas

  摘要：

  One-pot parallel synthesis of unsymmetrical aliphatic ureas was achieved with bis(2,2,2-trifluoroethyl) carbonate. The procedure worked well for both the monosubstituted and functionalized alkyl amines and required no special conditions (temperature control, order, or rate of addition). A library of 96 diverse ureas was easily synthesized.

  DOI：

  10.1021/co500025f

文献信息

• PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：BENAZET ALEXANDRE

  公开号：US20130079337A1

  公开（公告）日：2013-03-28

  The invention relates to compounds corresponding to formula (I) in which R1, R2 and R3 are as defined in Claim 1 , and also to the process for preparing them and to their therapeutic use.

  这项发明涉及与式（I）相对应的化合物，其中R1、R2和R3如权利要求1中所定义的，并且还涉及制备它们的过程以及它们的治疗用途。
• [EN] DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS<br/>[FR] DÉRIVÉS DE 2H-PYRIDAZIN-3-ONES, LEUR PRÉPARATION ET LEUR UTILISATION COMME INHIBITEURS DE LA SCD-1
  申请人：PF MEDICAMENT

  公开号：WO2011015629A1

  公开（公告）日：2011-02-10

  The present invention concerns compounds of general formula (I) characterized in that (formula 1) wherein, in particular: -R1 represents one or more groups such as: trif luoromethyl, halogen such as F, C1, -when n=m=1, W represents CH then Y represents oxygen, -U represents: • either - (C=O) CH2NH- and is branched at position 4 of pyridazinone, then R2 represents H, • or -(C=O)NH- and U is branched at positions (4), (5) or (6) of pyridazinone, then R2 represents H, - R3 represents a hydrogen or methyl and the addition salts with pharmaceutically acceptable bases and acids and the different isomers, and their mixtures in any proportion for use as SCD-1 enyzme inhibitors for the treatment of obesitz, tzpe-2 diabetes and lipid disorders.

  本发明涉及一般式(I)的化合物，其特征在于（式1），其中，特别是： -R1代表三氟甲基、氟、C1等一种或多种基团， -当n=m=1时，W代表CH，Y代表氧， -U代表： • 要么是-(C=O)CH2NH-并且在吡啶并酮的4位分支，然后R2代表H， • 要么是-(C=O)NH-并且U在吡啶并酮的(4)、(5)或(6)位分支，然后R2代表H， -R3代表氢或甲基，以及与药用可接受的碱和酸形成的加合物，以及不同的异构体，以及它们在任何比例下的混合物，用作SCD-1酶抑制剂，用于治疗肥胖症、2型糖尿病和脂质紊乱。
• DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS
  申请人：Dupont-Passelaigue Elisabeth

  公开号：US20120178678A1

  公开（公告）日：2012-07-12

  The present invention concerns compounds of general formula (I) characterized in that (formula 1) wherein, in particular: —R 1 represents one or more groups such as: trifluoromethyl, halogen such as F, Cl, —when n=m=1, W represents CH then Y represents oxygen, —U represents: either —(C═O)CH 2 NH— and is branched at position 4 of pyridazinone, then R2 represents H, or —(C═O)NH— and U is branched at positions (4), (5) or (6) of pyridazinone, then R2 represents H, —R3 represents a hydrogen or methyl and the addition salts with pharmaceutically acceptable bases and acids and the different isomers, and their mixtures in any proportion for use as SCD-1 enzyme inhibitors for the treatment of obesity, type-2 diabetes and lipid disorders.

  本发明涉及一般式(I)的化合物，其特征在于（公式1），其中特别地： - R1表示三氟甲基、卤素（如F、Cl）等一个或多个基团； - 当n=m=1时，W表示CH，Y表示氧； - U表示：要么是(C═O)CH2NH，且在吡嗪酮的位置4处分支，此时R2表示H；要么是(C═O)NH，且U在吡嗪酮的位置(4)、(5)或(6)处分支，此时R2表示H； - R3表示氢或甲基； - 以及它们与药用可接受的酸和碱形成的加合物和不同的异构体，以及它们在任意比例下混合，作为SCD-1酶抑制剂，用于治疗肥胖症、2型糖尿病和脂质代谢紊乱。
• Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors
  申请人：Dupont-Passelaigue Elisabeth

  公开号：US08946225B2

  公开（公告）日：2015-02-03

  The present invention concerns compounds of general formula (I) characterized in that (formula 1) wherein, in particular: —R1 represents one or more groups such as: trifluoromethyl, halogen such as F, Cl, —when n=m=1, W represents CH then Y represents oxygen, —U represents: •either —(C═O)CH2NH— and is branched at position 4 of pyridazinone, then R2 represents H, •or —(C═O)NH— and U is branched at positions (4), (5) or (6) of pyridazinone, then R2 represents H, —R3 represents a hydrogen or methyl and the addition salts with pharmaceutically acceptable bases and acids and the different isomers, and their mixtures in any proportion for use as SCD-1 enzyme inhibitors for the treatment of obesity, type-2 diabetes and lipid disorders.

  本发明涉及一般式（I）的化合物，其特征在于（公式1）其中，特别是：-R1表示诸如三氟甲基、卤素（如F、Cl）等一种或多种基团，当n=m=1时，W表示CH，然后Y表示氧，-U表示：•要么是-(C═O)CH2NH-并在吡啶并咪唑酮的4位分支，然后R2表示H，•要么是-(C═O)NH-并且U在吡啶并咪唑酮的（4）、（5）或（6）位分支，然后R2表示H，-R3表示氢或甲基，以及与药学上可接受的酸和碱的加合物和不同的异构体，以及它们在任何比例下混合，用作SCD-1酶抑制剂，用于治疗肥胖症、2型糖尿病和脂质紊乱。
• DERIVATIVES OF 2H PYRIDAZIN-3-ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS
  申请人：Pierre Fabre Médicament

  公开号：EP2462121B1

  公开（公告）日：2015-02-18